Form 4: TScan Therapeutics Executive Granted Stock Options
SEC Form 4 Filing
Chrystal Louis, Chief Medical Officer of TScan Therapeutics, acquired stock options for 400,000 shares on January 3, 2025.
Summary
- Chrystal Louis, the Chief Medical Officer of TScan Therapeutics, was granted stock options.
- The transaction occurred on January 3, 2025.
- The stock options are for 400,000 shares of TScan Therapeutics (TCRX).
- The exercise price of the options is $3.065.
- The options vest over a four-year period, with 25% vesting on the one-year anniversary of the grant date and the remainder vesting monthly over the subsequent 36 months.
- The options expire on January 3, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.
Positives
- The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term commitment and performance.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. This grant is typical for a Chief Medical Officer role.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also utilize stock options to incentivize their executives.
- The vesting schedule of 25% after one year followed by monthly vesting is a common practice to ensure continued service.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning the Chief Medical Officer's interests with the company's long-term success.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of the stock option grant and earliest transaction. |
| 01/03/2026 | First vesting date for 25% of the stock options. |
| 01/03/2035 | Expiration date of the stock options. |
| 02/11/2025 | Date of the Form 4 filing. |
Keywords
stock options, TScan Therapeutics, TCRX, Chief Medical Officer, Chrystal Louis, executive compensation, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.